BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

NS Pharma Parent Nippon Shinyaku Secures Global Option Rights to Develop Elixirgen's DMD Therapy EXG-7001

NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon S...

June 30, 2026 | News

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 for EGFR-Mutant Lung Cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung ...

June 29, 2026 | News

Everest Medicines' LEROCHOL® BLA Accepted in China for Third-Generation PCSK9 Inhibitor

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

June 29, 2026 | News

HKeyBio Launches NHP Fast-Tox Program to Accelerate Early Safety Assessment for Biologics

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics an...

June 26, 2026 | News

Abbisko Therapeutics Expands Strategic Alliance with Lilly in Multi-Target Drug Discovery Deal Worth Up to $1.9 Billion

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collab...

June 25, 2026 | News

AnHorn Medicines Secures FDA IND Clearance for First-in-Class CIPN Prevention Candidate

AnHorn Medicines announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuro...

June 24, 2026 | News

China Approves World's First CAR-T Therapy for Solid Tumours

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...

June 24, 2026 | News

Avance Clinical Expands APAC And China Operations To Accelerate Global Biotech Trials

Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pacif...

June 22, 2026 | News

Qihan Biotech’s Universal CAR-T Therapy QT-019B Secures FDA’s ‘Triple Crown’ of Expedited Designations

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...

June 18, 2026 | News

Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat

Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...

June 18, 2026 | News

Pelago Bioscience Acquires RG Discovery to Create Integrated Chemistry-to-Biology Drug Discovery Platform

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement as...

June 17, 2026 | News

Lilly's Jaypirca Combination Cuts Disease Progression Risk by 45% in Relapsed CLL Phase 3 Trial

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the...

June 16, 2026 | News

Stay Connected